Dr. Adi Diab on Baseline Tumor Immune Signatures and Therapy Response in Solid Tumors
Cancer Network spoke with Adi Diab, MD, of MD Anderson Cancer Center, on the link between baseline tumor immune signatures and response to bempegaldesleukin and nivolumab in patients with advanced solid tumors.
Cancer Network spoke with Adi Diab, MD, of The University of Texas MD Anderson Cancer Center, regarding the results of the phase I/II PIVOT-02 trial. He and fellow investigators are exploring the association between baseline tumor immune signatures and response to bempegaldesleukin (NKTR-214) and nivolumab in patients with advanced solid tumors. The results (abstract 2623) were presented at ASCO 2019.
Recent Videos
Related Content
